Composite cardiometabolic outcome

Biomarker1 paper1 finding

Humans1

Associations

1

Urate-lowering therapy

upin humans1HR 1.18Low certainty

1 study

Urate-lowering therapy raises the risk of composite cardiometabolic outcome in humans (HR 1.18, 95% CI 1.07-1.30).
Humansmedian follow-up of 3.03 years
Early urate-lowering therapy and cardiometabolic risk in adults without documented major cardiometabolic disease: a real-world cohort study · Frontiers in endocrinology · 31 Aug 2026

Urate-lowering therapy →

Latest

1

Frontiers in EndocrinologyHumans15 Sep

Early urate-lowering therapy and cardiometabolic risk in adults without documented major cardiometabolic disease: a real-world cohort study